Who are RBV(24 weeks)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Continue Ritonavir-boosted PI+Rosuvastatin, Reyataz + Epzicom, Darunavir/Ritonavir (Prezista), PEP, AZT+3TC+IDV+RTV, Standard-of-care Antiretroviral therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rbv-24-weeks.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

RBV(24 weeks) — Competitive Intelligence Brief

RBV(24 weeks) (RBV(24 weeks)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: protease inhibitor. Area: Infectious Disease.

phase 3 protease inhibitor HIV protease Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

RBV(24 weeks) (RBV(24 weeks)) — Tanabe Pharma Corporation. Ritonavir is a protease inhibitor used to treat HIV/AIDS by preventing the replication of the virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RBV(24 weeks) TARGET	RBV(24 weeks)	Tanabe Pharma Corporation	phase 3	protease inhibitor	HIV protease
Continue Ritonavir-boosted PI+Rosuvastatin	Continue Ritonavir-boosted PI+Rosuvastatin	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + statin)	HIV protease (PI component); HMG-CoA reductase (rosuvastatin component)
Reyataz + Epzicom	Reyataz + Epzicom	ViiV Healthcare	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Darunavir/Ritonavir (Prezista)	Darunavir/Ritonavir (Prezista)	Kowa Research Institute, Inc.	marketed	HIV protease inhibitor	HIV protease
PEP	PEP	Christopher J. McLeod	marketed	Protease inhibitor	HIV protease
AZT+3TC+IDV+RTV	AZT+3TC+IDV+RTV	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease
Standard-of-care Antiretroviral therapy	Standard-of-care Antiretroviral therapy	Medical Research Council	marketed	Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors)	HIV reverse transcriptase, HIV protease, HIV integrase, HIV envelope glycoproteins (CCR5/CXCR4 co-receptors)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (protease inhibitor class)

Tibotec Pharmaceuticals, Ireland · 3 drugs in this class
AbbVie · 1 drug in this class
AbbVie (prior sponsor, Abbott) · 1 drug in this class
R-Pharm · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RBV(24 weeks) — Competitive Intelligence Brief. https://druglandscape.com/ci/rbv-24-weeks. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab